A kinetic enzyme-linked immunosorbent assay (ELISA) for plasma tissue inhibitor of metalloproteinase (TIMP)-1 was developed in order to examine the potential diagnostic and prognostic value of TIMP-1 measurements in cancer patients. The ELISA enabled specific detection of total TIMP-1 in EDTA, citrate and heparin plasma. The assay was rigorously tested and requirements of sensitivity, specificity, stability and good recovery were fulfilled. TIMP-1 levels measured in citrate plasma (mean 69.2 ± 13.1 μg l–1) correlated with TIMP-1 measured in EDTA plasma (mean 73.5 ± 14.2 μg l–1) from the same individuals in a set of 100 healthy blood donors (Spearman’s rho = 0.62, P < 0.0001). The mean level of TIMP-1 in EDTA plasma from 143 patients with Dukes’ stage D colorectal cancer was 240 ± 145 μg l–1 and a Mann–Whitney test demonstrated a highly significant difference between TIMP-1 levels in healthy blood donors and colorectal cancer patients (P < 0.0001). Similar findings were obtained for 19 patients with advanced breast cancer (mean 292 ± 331 μg l–1). The results show that TIMP-1 is readily measured in plasma samples by ELISA and that increased levels of TIMP-1 are found in patients with advanced cancer. It is proposed that plasma measurements of TIMP-1 may have value in the management of cancer patients.
Baker, T., Tickle, S., Wasan, H., Docherty, A., Isenberg, D. & Waxman, J. (1994). Serum metalloproteinases and their inhibitors: markers for malignant potential. Br J Cancer 70: 506–512.
Birkedal-Hansen, H., Moore, W. G., Bodden, M. K., Windsor, L. J., Birkedal-Hansen, B., DeCarlo, A. & Engler, J. A. (1993). Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4: 197–250.
Clark, I. M., Powell, L. K., Wright, J. K. & Cawston, the (1991). Polyclonal and monoclonal antibodies against human tissue inhibitor of metalloproteinases (TIMP) and the design of an enzyme-linked immunosorbent assay to measure TIMP. Matrix 11: 76–85.
Cooksley, S., Hipkiss, J. B., Tickle, S. P., Holmes, I. E., Docherty, A. J., Murphy, G. & Lawson, A. D. (1990). Immunoassays for the detection of human collagenase, stromelysin, tissue inhibitor of metalloproteinases (TIMP) and enzyme-inhibitor complexes. Matrix 10: 285–291.
Cooper, T. W., Eisen, A. Z., Stricklin, G. P. & Welgus, H. G. (1985). Platelet-derived collagenase inhibitor: characterization and subcellular localization. Proc Natl Acad Sci USA 82: 2779–2783.
De Nictolis, M., Garbisa, S., Lucarini, G., Goteri, G., Masiero, L., Ciavattini, A., Garzetti, G. G., Stetler-Stevenson, W. G., Fabris, G., Biagini, G. & Prat, J. (1996). 72-kilodalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors or the ovary: a clinicopathologic, immunohistochemical, and serological study. Int J Gynecol Pathol 15: 102–109.
DeClerck, Y. A., Perez, N., Shimada, H., Boone, T. C., Langley, K. E. & Taylor, S. M. (1992). Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 52: 701–708.
Deng, G., Curriden, S. A., Wang, S., Rosenberg, S. & Loskutoff, D. J. (1996). Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134: 1563–1571.
Fong, K. M. (1996). TIMP1 and adverse prognosis in non-small cell lung cancer. Clin Cancer Res 2: 1369–1372.
Frandsen, T. L., Stephens, R. W., Pedersen, A. N., Engelholm, L. H., Holst-Hansen, C. & Brünner, N. (1998). Plasminogen activator inhibitor type 1 (PAI-1) in cancer: a potential new target for antiinvasive and antimetastatic therapy. Drugs of the Future 23: 873–883.
Fujimoto, N., Zhang, J., Iwata, K., Shinya, T., Okada, Y. & Hayakawa, T. (1993). A one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases-2 using monoclonal antibodies. Clin Chim Acta 220: 31–45.
Fung, K., Nowak, L., Lein, M., Henke, W., Schnorr, D. & Loening, S. A. (1996). Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors in blood. Clin Chem 42: 2043–2045.
Gohji, K., Fujimoto, N., Fujii, A., Komiyama, T., Okawa, J. & Nakajima, M. (1996). Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res 56: 3196–3198.
Goldberg, G. I., Strongin, A., Collier, I. E., Genrich, L. T. & Marmer, B. L. (1992). Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 267: 4583–4591.
Hayakawa, T., Yamashita, K., Tanzawa, K., Uchijima, E. & Iwata, K. (1992). Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 298: 29–32.
Hembry, R. M., Murphy, G. & Reynolds, J. J. (1985). Immunolocalization of tissue inhibitor of metalloproteinases (TIMP) in human cells. Characterization and use of a specific antiserum. J Cell Sci 73: 105–119.
Jung, K., Nowak, L., Lein, M., Henke, W., Schnorr, D. & Loening, S. A. (1996). What kind of specimen should be selected for determining tissue inhibitor of metalloproteinase-1 (TIMP-1) in blood? Clin Chim Acta 254: 97–100.
Kawano, N., Osawa, H., Ito, T., Nagashima, Y., Hirahara, F., Inayama, Y., Nakatani, Y., Kimura, S., Kitajima, H., Koshikawa, N., Miyazaki, K. & Kitamura, H. (1997). Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. Hum Pathol 28: 613–622.
Khokha, R. & Waterhouse, P. (1993). The role of tissue inhibitor of metalloproteinase-1 in specific aspects of cancer progression and reproduction. J Neurooncol 18: 123–127.
Khokha, R., Zimmer, M. J., Graham, C. H., Lala, P. K. & Waterhouse, P. (1992a). Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in B16-F10 melanoma cells. J Natl Cancer Inst 84: 1017–1022.
Khokha, R., Zimmer, M. J., Wilson, S. M. & Chambers, A. F. (1992b). Up-regulation of TIMP-1 expression in B16-F10 melanoma cells suppresses their metastatic ability in chick embryo. Clin Exp Metastasis 10: 365–370.
Kleiner, Jr D. E., Tuuttila, A., Tryggvason, K. & Stetler-Stevenson, W. G. (1993). Stability analysis of latent and active 72-kDa type IV collagenase: the role of tissue inhibitor of metalloproteinases-2 (TIMP-2). Biochemistry 32: 1583–1592.
Kodama, S., Yamashita, K., Kishi, J., Iwata, K. & Hayakawa, T. (1989). A sandwich enzyme immunoassay for collagenase inhibitor using monoclonal antibodies. Matrix 9: 1–6.
Liotta, L. A., Steeg, P. S. & Stetler-Stevenson, W. G. (1991). Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327–336.
MacDougall, J. R. & Matrisian, L. M. (1995). Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev 14: 351–362.
Matrisian, L. M. (1992). The matrix-degrading metalloproteinases. Bioessays 14: 455–463.
Mimori, K., Mori, M., Shiraishi, T., Fujie, T., Baba, K., Haraguchi, M., Abe, R., Ueo, H. & Akiyoshi, T. (1997). Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer 76: 531–536.
Moll, U. M., Youngleib, G. L., Rosinski, K. B. & Quigley, J. P. (1990). Tumor promoter-stimulated Mr 92,000 gelatinase secreted by normal and malignant human cells: isolation and characterization of the enzyme from HT1080 tumor cells. Cancer Res 50: 6162–6170.
Moutsiakis, D., Mancuso, P., Krutzsch, H., Stetler-Stevenson, W. G. & Zucker, S. (1992). Characterization of metalloproteinases and tissue inhibitors of metalloproteinases in human plasma. Connect Tissue Res 28: 213–230.
Murphy, G., Houbrechts, A., Cockett, M. I., Williamson, R. A., O’Shea, M. & Docherty, A. J. (1991). The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry 30: 8097–8102.
Nuovo, G. J., MacConnell, P. B., Simsir, A., Valea, F. & French, D. L. (1995). Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 55: 267–275.
Stetler-Stevenson, W. G., Krutzsch, H. C. & Liotta, L. A. (1989). Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 264: 17374–17378.
Stetler-Stevenson, W. G., Liotta, L. A. & Kleiner, Jr D. E. (1993). Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 7: 1434–1441.
Stetler-Stevenson, W. G., Hewitt, R. & Corcoran, M. (1996). Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 7: 147–154.
Thorgeirsson, U. P., Lindsay, C. K., Cottam, D. W. & Gomez, D. E. (1993). Tumor invasion, proteolysis, and angiogenesis. J Neurooncol 18: 89–103.
Welgus, H. G., Jeffrey, J. J., Eisen, A. Z., Roswit, W. T. & Stricklin, G. P. (1985). Human skin fibroblast collagenase: interaction with substrate and inhibitor. Coll Relat Res 5: 167–179.
Wilhelm, S. M., Collier, I. E., Marmer, B. L., Eisen, A. Z., Grant, G. A. & Goldberg, G. I. (1989). SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 264: 17213–17221.
Yoshiji, H., Gomez, D. E. & Thorgeirsson, U. P. (1996). Enhanced RNA expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in human breast cancer. Int J Cancer 69: 131–134.
Zucker, S., Lysik, R. M., DiMassimo, B. I., Zarrabi, H. M., Moll, U. M., Grimson, R., Tickle, S. P. & Docherty, A. J. (1995). Plasma assay of gelatinase B: tissue inhibitor of metalloproteinase complexes in cancer. Cancer 76: 700–708.
About this article
Cite this article
Holten-Andersen, M., Murphy, G., Nielsen, H. et al. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 80, 495–503 (1999). https://doi.org/10.1038/sj.bjc.6690384
- blood donors
Pathology & Oncology Research (2019)
Tissue inhibitor of matrix metalloproteinase-1 expression in colorectal cancer liver metastases is associated with vascular structures
Molecular Carcinogenesis (2016)
Comparative studies of TIMP-1 immunohistochemistry, TIMP-1 FISH analysis and plasma TIMP-1 in glioblastoma patients
Journal of Neuro-Oncology (2016)
Circulating intact and cleaved forms of the urokinase-type plasminogen activator receptor: Biological variation, reference intervals and clinical useful cut-points
Clinica Chimica Acta (2015)
Serum metalloproteinase-9 is related to COPD severity and symptoms - cross-sectional data from a population based cohort-study
Respiratory Research (2015)